Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Double-blind, Randomized, Active Comparator-controlled, Group-sequential, Multinational Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants

NCT04010448 is registered in ClinicalTrials.gov with PATH as lead sponsor.

NCT NCT04010448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04010448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Double-blind, Randomized, Active Comparator-controlled, Group-sequential, Multinational Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants
Lead sponsor
PATH
Phase
Phase 3
Overall status
Unknown status
Start date
October 10, 2019
Completion date
December 15, 2025
Enrollment
8,200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rotavirus infection of children